A total of 66 mutated genes and 488 mutation sites were detected in 82.33% (261 of 317) of the NSCLC patients, among which the most frequently mutated genes were EGFR (59.94%), followed by TP53 (43.85%), NRG1 (9.46%), PIK3CA (6.31%), ATM (5.36%), APC (4.42%), ARID1A (4.42%), BRAF (4.10%), NTRK1 (4.10%), POLE (4.10%) and KRAS (3.79%). This evidence concerns the gene BRAF and non-small cell lung carcinoma.